ImmunityBio, Inc. - Common Stock (NQ:IBRX)

10.33 +0.05 (+0.49%)

Delayed Quote Updated: 10:24 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Li Auto Posts Q4 Earnings, Joins Teva Pharmaceutical And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

February 26, 2024

U.S. stock futures were lower this morning, with the Dow futures trading lower by over 50 points on Monday.

Via Benzinga

Topics Stocks

Why MercadoLibre Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 23, 2024

Shares of MercadoLibre, Inc. (NASDAQ: MELI) fell sharply during Friday’s session after the company reported fourth-quarter financial results.

Via Benzinga

NASDAQ:IBRX Long Term Investor Alert: Investigation over Potential Wrongdoing at ImmunityBio, Inc. ↗

November 03, 2023

San Diego, CA -- (SBWIRE) -- 11/03/2023 -- Certain directors of ImmunityBio, Inc. are under investigation over potential breaches of fiduciary duties.

Via SBWire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 23, 2024

Via Benzinga

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

February 21, 2024

From ImmunityBio

Via Business Wire

Analysts see over 50% gains in these 2 mid-cap biotech stocks

February 14, 2024

The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.

Via MarketBeat

Topics Artificial Intelligence

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

February 05, 2024

From ImmunityBio, Inc.

Via Business Wire

M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024 ↗

January 02, 2024

Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024.

Via InvestorPlace

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

January 02, 2024

From ImmunityBio, Inc.

Via Business Wire

Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 23, 2024

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.

Via Benzinga

Why Rocket Lab Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

December 22, 2023

Shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) shares rose sharply in pre-market trading after the company announced a new $515 million contract with a U.S. government customer.

Via Benzinga

Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

December 22, 2023

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

Via Benzinga

Toro Posts Upbeat Results, Joins Clear Channel Outdoor, Marathon Digital And Other Big Stocks Moving Higher On Wednesday ↗

December 20, 2023

U.S. stocks traded mixed, with the Dow Jones index falling around 50 points on Wednesday.

Via Benzinga

Topics Stocks

Jim Cramer Likes This Industrial Stock 'Even Up Here,' As For ImmunityBio? 'It's Risky' ↗

December 04, 2023

On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Trane Technologies plc (NYSE: TT) so much.

Via Benzinga

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

November 16, 2023

From ImmunityBio, Inc.

Via Business Wire

7 Small-Cap Stocks With Massive Growth Potential ↗

November 09, 2023

Small-cap stocks can generate oversized returns, particularly when they hit on a new product or provide a unique service.

Via InvestorPlace

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

November 07, 2023

From ImmunityBio, Inc.

Via Business Wire

3 Biotech Moonshots to Bet on the Future of Health ↗

November 06, 2023

Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.

Via InvestorPlace

Topics Intellectual Property

TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday ↗

November 06, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Topics Stocks

Should You Still Buy the Nasdaq's Best-Performing October Stocks? ↗

November 03, 2023

Last month's big winners were tricky to handle due to the amount of speculation investors were willing to do with them.

Via The Motley Fool

Western Digital, JinkoSolar, Lumentum Holdings And Other Big Stocks Moving Higher On Monday ↗

October 30, 2023

U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why ON Semiconductor Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 30, 2023

Gainers Miromatrix Medical Inc. (NASDAQ: MIRO) shares climbed 230.7% to $3.3401 after United Therapeutics agreed to acquire the company for $3.25 per share in cash.

Via Benzinga

Chipotle, Amazon, Deckers Outdoor, Capital One And Other Stocks Move Higher On Friday ↗

October 27, 2023

U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Why Barnes Group Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

October 27, 2023

Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion.

Via Benzinga

Ford, Sanofi, Enphase Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

October 27, 2023

U.S. stock futures traded higher this morning on Friday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

October 26, 2023

Gainers

Via Benzinga

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date

October 26, 2023

From ImmunityBio, Inc.

Via Business Wire

IBM, ServiceNow, Lennox, Morningstar And Other Big Stocks Moving Higher On Thursday ↗

October 26, 2023

U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recording gains in today’s session.

Via Benzinga

Topics Stocks

Alphabet, Texas Instruments, CoStar Group And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 25, 2023

U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why Asbury Automotive Group Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

October 24, 2023

Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's drug candidate following proof-of-concept study data.

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.